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Immunomediated growth and regression of pancreatic tumors in 
vivo
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We are using a novel spontaneous pancreatic adenocarci-
noma tumor model to investigate immunotherapeutic
approaches against pancreatic cancer.
Crossbreeding of p53 knockout mice with TGF-α trans-
genic mice which overexpress TGF-α in the pancreas and
thus develop fibrosis and ductual pancreatic cancer at the
age of one year dramatically accelerates tumor develop-
ment and represents the first model of pancreatic adeno-
carcinoma with genetic alterations as well as
characteristics similar to the human disease.
We have established a total of 28 murine adenopancreatic
cell lines (mPACs) derived from 6 different TGF-α p53-/-
mice. In vivo growth kinetics were analysed in normal syn-
genic mice and showed that some cell lines progress after
in vivo injection to form lethal tumors while others grow
during the first 10 days and then regress. Next, these
tumors were injected into scid beige and in nude mice. In
these mice progressors and regressors grow progressively
indicating that the regression in normal euthymic mice is
an immunemediated response.
Cytotoxic T cell responses against MHC I positive mPACs
are induced after immunization with irradiated mPACs
and can be found in mice with spontaneous pancreatic
carcinomas. Injection of mPAC leads to the induction of
IFN-γ secrting CD8 T cells in vivo, which can also be found
in tumor bearing mice.
This new model opens the possibility to investigate
sponatneous immune responses against pancreatic can-
cers in a gentically well defined tumor model, which mim-
icks human adenocarcinoma.
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